Myocardial Positron Emission Tomography for Evaluation of Cardiac Sarcoidosis: Specialized Protocols for Better Diagnosis

키워드

참고문헌 (56)

1. Porter GH, "Sarcoid heart disease", N Engl J Med, 263, pp.1350~1357 (1960)
2. Birnie DH, "Cardiac Sarcoidosis", J Am Coll Cardiol, 68, pp.411~421 (2016)
3. Silverman KJ, "Cardiac sarcoid : a clinicopathologic study of 84 unselected patients with systemic sarcoidosis", Circulation, 58, pp.1204~1211 (1978)
4. Bennett MK, "Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009", Circ Heart Fail, 6, pp.676~684 (2013)
5. Birnie DH, "HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis", Heart Rhythm, 11, pp.1305~1323 (2014)
6. JCS Joint Working Group, "Guidelines for diagnosis and treatment of myocarditis(JCS 2009) : digest version", Circ J, 75, pp.734~743 (2011)
7. Aggarwal NR, "Advances in imaging for diagnosis and management of cardiac sarcoidosis", Eur Heart J Cardiovasc Imaging, 16, pp.949~958 (2015)
8. Blankstein R, "Evaluation of known or suspected cardiac sarcoidosis", Circ Cardiovasc Imaging, 9, pp.e000867~ (2016)
9. Ohira H, "Clinical application of 18F-fluorodeoxyglucose PET and LGE CMR in cardiac sarcoidosis", Ann Nucl Cardiol, 3, pp.125~130 (2017)
10. Okumura W, "Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis", J Nucl Med, 45, pp.1989~1998 (2004)
11. Nishiyama Y, "Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis", J Nucl Med, 47, pp.1571~1576 (2006)
12. Ishida Y, "Recommendations for(18)F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis : Japanese Society of Nuclear Cardiology recommendations", Ann Nucl Med, 28, pp.393~403 (2014)
13. Wisneski JA, "Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans", J Clin Invest, 79, pp.359~366 (1987)
14. Santalucía T, "Developmental regulation of GLUT-1 (erythroid", Hep G2) and GLUT-4 (muscle, Endocrinology, pp.1992, 130[DOI]
15. Montessuit C, "Regulation and dysregulation of glucose transport in cardiomyocytes", Biochim Biophys Acta, 1833, pp.848~856 (2013)
16. Randle PJ, "The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus", Lancet, 1, pp.785~789 (1963)
17. Nuutila P, "Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo", J Clin Invest, 89, pp.1767~1774 (1992)
18. Kubota K, "Re-evaluation of myocardial FDG uptake in hyperglycemia", J Nucl Med, 37, pp.1713~1717 (1996)
19. Yamada K, "Experimental studies on myocardial glucose metabolism of rats with 18F-2-fluoro-2-deoxy-D-glucose", Eur J Nucl Med, 10, pp.341~345 (1985)
20. Miyagawa M, "Positron emission tomography-computed tomography for imaging of inflammatory cardiovascular diseases", Circ J, 78, pp.1302~1310 (2014)
21. Wieman HL, "Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase", Akt regulation of Glut1 activity and trafficking, 2007, pp.18, 1437~1446
22. Kominsky DJ, "Metabolic shifts in immunity and inflammation", J Immunol, 184, pp.4062~4068 (2010)
23. Maratou E, "Glucose transporter expression on the plasma membrane of resting and activated white blood cells", Eur J Clin Invest, 37, pp.282~290 (2007)
24. Simpson IA, "The facilitative glucose transporter GLUT3 : 20 years of distinction", Am J Physiol Endocrinol Metab, 295, pp.E242~E253 (2008)
25. Youssef G, "The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis : a systematic review and metaanalysis including the Ontario experience", J Nucl Med, 53, pp.241~248 (2012)
26. Yokoyama R, "Quantitative analysis of myocardial 18F-fluorodeoxyglucose uptake by PET", CT for detection of cardiac sarcoidosis, 2015, pp.195, 180~187
27. Tahara N, "Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis", JACC Cardiovasc Imaging, 3, pp.1219~1228 (2010)
28. Sperry BW, "Prognostic impact of extent, severity, and heterogeneity of abnormalities on (18)F-FDG PET scans for suspected cardiac sarcoidosis", JACC Cardiovasc Imaging, 11, pp.336~345 (2018)
29. Ahmadian A, "Quantitative interpretation of FDG PET", CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis, 2014, pp.21, 925~939
30. Blankstein R, "Maximizing the prognostic value of cardiac PET in patients with suspected cardiac sarcoidosis : a simple semiquantitative score may help", JACC Cardiovasc Imaging, 11, pp.346~348 (2018)
31. Boellaard R, "FDG PET", CT: EANM procedure guidelines for tumour imaging: version 2.0, 2015, pp.42, 328~354
32. Lindholm P, "Influence of the blood glucose concentration on FDG uptake in cancer--a PET study", J Nucl Med, 34, pp.1~6 (1993)
33. Chareonthaitawee P, "Joint SNMMI-ASNC expert consensus document on the role of(18)F-FDG PET", CT in cardiac sarcoid detection and therapy monitoring, 2017, pp.58, 1341~1353
34. Morooka M, "Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis", EJNMMI Res, 4, pp.1~ (2014)
35. Ishimaru S, "Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis", Eur Heart J, 26, pp.1538~1543 (2005)
36. Ohira H, "Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis", Eur J Nucl Med Mol Imaging, 35, pp.933~941 (2008)
37. Langah R, "Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis", J Nucl Cardiol, 16, pp.801~810 (2009)
38. Persson E, "Plasma lipolytic activity after subcutaneous administration of heparin and a low molecular weight heparin fragment", Thromb Res, 46, pp.697~704 (1987)
39. Persson E, "Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin)", Acta Med Scand Suppl, 724, pp.1~56 (1988)
40. fluoro-D-glucose uptake artifacts in positron emission tomography using dietary carbohydrate restriction, "Mol Imaging Biol", 2002, 232~237
41. Cheng VY, "Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET : A randomized controlled trial", J Nucl Cardiol, 17, pp.286~291 (2010)
42. Ohira H, "¹⁸F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis", Eur J Nucl Med Mol Imaging, 38, pp.1773~1783 (2011)
43. Wykrzykowska J, "Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET", CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation, 2009, pp.50, 563~568
44. Williams G, "Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet", AJR Am J Roentgenol, 190, pp.W151~W156 (2008)
45. Harisankar CN, "Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake", J Nucl Cardiol, 18, pp.926~936 (2011)
46. Demeure F, "A randomized trial on the optimization of 18F-FDG myocardial uptake suppression : implications for vulnerable coronary plaque imaging", J Nucl Med, 55, pp.1629~1635 (2014)
47. Dilsizian V, "ASNC imaging guidelines", SNMMI procedure standard for positron emission tomography(PET)nuclear cardiology procedures, 2016, pp.23, 1187~1226
48. Hamzeh N, "Pathophysiology and clinical management of cardiac sarcoidosis", Nat Rev Cardiol, 12, pp.278~288 (2015)
49. Blankstein R, "Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis", J Am Coll Cardiol, 63, pp.329~336 (2014)
50. Yamagishi H, "Identification of cardiac sarcoidosis with(13)N-NH(3)", (18)F-FDG PET, 2003, pp.44, 1030~1036
51. Tadamura E, "Images in cardiovascular medicine. Multimodality imaging of cardiac sarcoidosis before and after steroid therapy", Circulation, 113, pp.e771~e773 (2006)
52. Ahmadian A, "The response of FDG uptake to immunosuppressive treatment on FDG PET", CT imaging for cardiac sarcoidosis, 2017, pp.24, 413~424
53. Lee PI, "The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis", J Nucl Cardiol, 24, pp.19~28 (2017)
54. Osborne MT, "Reduction in ¹⁸F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis", J Nucl Cardiol, 21, pp.166~174 (2014)
55. Shelke AB, "Serial FDG-PET scans help to identify steroid resistance in cardiac sarcoidosis", Int J Cardiol, 228, pp.717~722 (2017)
56. Dweck MR, "Hybrid magnetic resonance imaging and positron emission tomography with fluorodeoxyglucose to diagnose active cardiac sarcoidosis", JACC Cardiovasc Imaging, 11, pp.94~107 (2018)

관련 논문AI추천